No Data
No Data
No Data
Clarus Files for Chapter 11 Bankruptcy, Eyes Auction of Testosterone Therapy Jatenzo
Clarus Therapeutics (OTCPK:CRXT) filed voluntary petitions under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware and want to pursue an auction and sale of its only commercial asse
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code
Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Hol
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results
NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and w
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022 Initiation of Phase 2 clinical trial for CLAR
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by ad
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by ad
No Data